Sugi Predict

Sugi Predict / Compounds / SCHEMBL589718

SCHEMBL589718

SCHEMBL589718

COc1ccc(S(=O)(=O)Cc2cc(C)on2)cc1-c1cnc(N)nc1Nc1ccc2c(C)n[nH]c2c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ METAP2 P50579 2/20 0.37
▸ GRM4 Q14833 1/20 0.34
▸ KDR P35968 2/20 0.34
▸ EPHA2 P29317 1/20 0.34
▸ BRAF P15056 1/20 0.32
▸ TP53 P04637 1/20 0.32
▸ MAPK1 P28482 2/20 0.32
▸ KCNH2 Q12809 2/20 0.32
▸ TLR7 Q9NYK1 2/20 0.32
▸ PIK3CA P42336 2/20 0.31
▸ CCNT1 O60563 1/20 0.31
▸ CDK9 P50750 1/20 0.31
▸ L3MBTL1 Q9Y468 2/20 0.31
▸ MEN1 O00255 2/20 0.31
▸ KMT2A Q03164 2/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ NSD2 O96028 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ POLB P06746 1/20 0.31
▸ GAA P10253 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL588945 0.88 MEN1 (0.38) KDRBRAFTP53PIK3CACCNT1
SCHEMBL588665 0.85 PDE5A (0.36) KDRBRAFTP53PIK3CAL3MBTL1
SCHEMBL31672509 0.78 KDR (0.41) METAP2GRM4KDRMAPK1CCNT1
SCHEMBL10151182 0.78 KDR (0.41) METAP2GRM4KDRMAPK1CCNT1
SCHEMBL30453816 0.75 METAP2 (0.34) METAP2
SCHEMBL589780 0.71 BRD4 (0.36) TP53
SCHEMBL12808485 0.71 KDM4E (0.36) METAP2KDM4EALDH1A1POLBMAPT
SCHEMBL588723 0.70 HRH4 (0.37) —
SCHEMBL1687025 0.70 ALK (0.40) KDR
SCHEMBL588668 0.69 LRRK2 (0.35) METAP2KDRTP53EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2311825-A1 Pyrimidineamines as angiogenesis modulators GlaxoSmithKline LLC (US) 2011-04-20 — — EP claimed
US-7262203-B2 Pyrimidineamines as angiogenesis modulators SMITHKLINE BEECHAM CORPORATION (US) 2007-08-28 — — US claimed
US-20070015756-A1 Chemical compounds NOVARTIS AG (CH) 2007-01-18 — — US claimed
US-20040242578-A1 Pyrimidineamines as angiogenesis modulators NOVARTIS AG (CH) 2004-12-02 — — US claimed
EP-3789027-A1 BOSUTINIB, SUNITINIB, TIVOZANIB, IMATINIB, NILOTINIB, REBASTINIB OR BAFETINIB FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS KYOTO UNIVERSITY (JP) 2021-03-10 — — EP disclosed
US-20180000771-A1 AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS KYOTO UNIVERSITY (JP) 2018-01-04 — — US disclosed
EP-3246046-A1 AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS Kyoto University (JP) 2017-11-22 — — EP disclosed
EP-2311825-B1 Pyrimidineamines as angiogenesis modulators NOVARTIS AG (CH) 2015-10-07 — — EP disclosed
US-20120277258-A1 Chemical Compounds LEO OSPREY LIMITED (JE) 2012-11-01 — — US disclosed
US-8114885-B2 Pazopanib hydrochloride and synthesis, chemical intermediates, and dosage forms thereof; anticancer; colon cancer, breast cancer GLAXOSMITHKLINE LLC (US) 2012-02-14 — — US disclosed
EP-2311825-A1 Pyrimidineamines as angiogenesis modulators GlaxoSmithKline LLC (US) 2011-04-20 — — EP disclosed
US-7858626-B2 Pyrimidineamines as angiogenesis modulators GLAXOSMITHKLINE LLC (US) 2010-12-28 — — US disclosed
US-20100105712-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2010-04-29 — — US disclosed
EP-1343782-B1 PYRIMIDINEAMINES AS ANGIOGENESIS MODULATORS SMITHKLINE BEECHAM CORP (US) 2009-05-06 — — EP disclosed
US-20070292513-A1 CHEMICAL COMPOUNDS NOVARTIS AG (CH) 2007-12-20 — — US disclosed
US-20070270427-A1 CHEMICAL COMPOUNDS NOVARTIS AG (CH) 2007-11-22 — — US disclosed
US-7262203-B2 Pyrimidineamines as angiogenesis modulators SMITHKLINE BEECHAM CORPORATION (US) 2007-08-28 — — US disclosed
US-20070015756-A1 Chemical compounds NOVARTIS AG (CH) 2007-01-18 — — US disclosed
US-7105530-B2 inhibitors of vascular endothelial growth factor receptor-2 kinase; pazopanib and salts; for proliferative retinopathy; anticancer SMITHKLINE BEECHAM CORPORATION (US) 2006-09-12 — — US disclosed
US-20040242578-A1 Pyrimidineamines as angiogenesis modulators NOVARTIS AG (CH) 2004-12-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242578-A1 Pyrimidineamines as angiogenesis modulators TYMS, TYMP, DPYD METAP2 1148/4885GRM4 3534/4885KDR 5/4885
US-20070015756-A1 Chemical compounds KDR, FLT4, FLT1 METAP2 2631/4885GRM4 4217/4885KDR 1/4885
US-20100105712-A1 CHEMICAL COMPOUNDS KDR, FLT4, FLT1 METAP2 2631/4885GRM4 4217/4885KDR 1/4885
US-20180000771-A1 AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS WEE2, WEE1, ERBB2 METAP2 2297/4885GRM4 1399/4885KDR 648/4885
US-20120277258-A1 Chemical Compounds KDR, FLT4, FLT1 METAP2 2631/4885GRM4 4217/4885KDR 1/4885
US-20070270427-A1 CHEMICAL COMPOUNDS KDR, FLT4, FLT1 METAP2 2631/4885GRM4 4217/4885KDR 1/4885
US-20070292513-A1 CHEMICAL COMPOUNDS KDR, FLT4, FLT1 METAP2 2631/4885GRM4 4217/4885KDR 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.